Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells

被引:30
作者
Fabbri, F
Brigliadori, G
Ulivi, P
Tesei, A
Vannini, I
Rosetti, M
Bravaccini, S
Amadori, D
Bolla, M
Zoli, W
机构
[1] Morgagni Pierantoni Hosp, Div Oncol & Diagnost, I-47100 Forli, Italy
[2] Morgagni Pierantoni Hosp, Ist Oncol Romagnolo, I-47100 Forli, Italy
[3] NicOx SA, Sophia Antipolis, France
关键词
apoptosis; bladder cancer; NO-NSAID;
D O I
10.1007/s10495-005-0619-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nitric oxide-releasing non steroidal anti-inflammatory drugs (NO-NSAIDs) are a promising class of compounds that cause cell cycle perturbations and induce apoptosis in cell lines from different tumors. We investigated the activity of a recently developed NO-NSAID (NCX 4040) in bladder cancer cell lines (HT1376 and MCR). Cells were treated with different drug concentrations for different exposure times. Cytostatic and cytocidal activity was tested by SRB assay and apoptosis was evaluated by TUNEL analysis, ANNEXIN V assay and fluorescence microscopy. To further investigate the cell death-inducing mechanisms of NCX 4040, we analyzed gp-170, caspase expression and mitochondrial membrane potential (Delta psi) depolarization. NCX 4040 showed a striking cytocidal activity in both cell lines, reaching LC50 at a 10-mu M and 50-mu M concentrations in HT1376 and in MCR cells, respectively, after an exposure of only 6 h followed by an 18-h washout. Apoptosis was triggered in up to 90% of cells and was associated with active caspase-3 expression and Delta psi depolarization in both cell lines after a 6-h exposure. In conclusion, NCX 4040, which probably causes apoptosis via a mitochondrial-dependent mechanism, could prove to be a useful agent for improving bladder cancer treatment.
引用
收藏
页码:1095 / 1103
页数:9
相关论文
共 30 条
[1]   Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction of NSAID-activated gene [J].
Baek, SJ ;
Wilson, LC ;
Lee, CH ;
Eling, TE .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (03) :1126-1131
[2]  
Bak AW, 1998, LIFE SCI, V62, pPL367
[3]   New drugs and new approaches in metastatic bladder cancer [J].
Bellmunt, J ;
de Wit, R ;
Albiol, S ;
Tabernero, J ;
Albanell, J ;
Baselga, J .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 47 (02) :195-206
[4]  
Castelao JE, 2000, BRIT J CANCER, V82, P1364
[5]   Therapeutic approaches to bladder cancer: identifying targets and mechanisms [J].
Cote, RJ ;
Datar, RH .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 46 :S67-S83
[6]   NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function [J].
Fiorucci, S ;
Mencarelli, A ;
Mannucci, R ;
Distrutti, E ;
Morelli, A ;
del Soldato, P ;
Moncada, S .
FASEB JOURNAL, 2002, 16 (10) :1645-+
[7]   NO-releasing NSAIDs are caspase inhibitors [J].
Fiorucci, S .
TRENDS IN IMMUNOLOGY, 2001, 22 (05) :232-235
[8]   TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS [J].
GIARDIELLO, FM ;
HAMILTON, SR ;
KRUSH, AJ ;
PIANTADOSI, S ;
HYLIND, LM ;
CELANO, P ;
BOOKER, SV ;
ROBINSON, CR ;
OFFERHAUS, GJA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (18) :1313-1316
[9]   Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines [J].
Huguenin, S ;
Vacherot, F ;
Fleury-Feith, J ;
Riffaud, JP ;
Chopin, DK ;
Bolla, M ;
Jaurand, MC .
CANCER LETTERS, 2005, 218 (02) :163-170
[10]  
Huguenin S, 2004, MOL CANCER THER, V3, P291